预约演示
更新于：2025-04-17
Cyclopentolate Hydrochloride
盐酸环喷托酯
更新于：2025-04-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1971-09-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H26ClNO3 |
InChIKeyRHKZVMUBMXGOLL-UHFFFAOYSA-N |
CAS号5870-29-1 |
关联
14
项与 盐酸环喷托酯 相关的临床试验TCTR20250312005
The comparative efficacy of a combination of 0.5% cyclopentolate tropicamide, and alternating instillation of 1% cyclopentolate and 1% tropicamide in Thai pediatric refraction
ChiCTR2400084750
Comparison of the effects of pupil dilation and ciliary muscle paralysis of 1% tropicamide, 0.5% tropicamide and 1% cyclopentolate
NCT06077682
Tropicamide Versus Cyclopentolate for Cycloplegic Refraction in Pediatric Patients With Esotropia: A Randomized Clinical Trial
100 项与 盐酸环喷托酯 相关的临床结果
登录后查看更多信息
100 项与 盐酸环喷托酯 相关的转化医学
登录后查看更多信息
100 项与 盐酸环喷托酯 相关的专利（医药）
登录后查看更多信息
690
项与 盐酸环喷托酯 相关的文献（医药）2025-03-03Cureus Journal of Medical Science
A Case of Pediatric Myasthenia Revealed by Marked Eyelid Ptosis After Using Cyclopentolate Eye Drops
Article
作者: Komatsu, Kaori ; Yoshikawa, Tomoko ; Kiuchi, Yoshiaki
Pediatric myasthenia gravis (PMG), while uncommon, poses significant diagnostic challenges due to its potential impact on development and its often subtle initial symptoms, such as ptosis and diplopia. This case report details an unusual presentation of PMG in a three-year-old female, initially diagnosed with a chalazion, highlighting the complexity of diagnosing this autoimmune neuromuscular disorder in children. Despite treatment for the assumed chalazion, the child's ptosis persisted, and disparities in visual acuity between her eyes became evident. The turning point in her diagnosis came during a routine ophthalmologic assessment using cyclopentolate hydrochloride, which exacerbated her ptosis, prompting further neuromuscular investigation. This led to the detection of acetylcholine receptor antibodies and a suspected diagnosis of PMG after a repetitive nerve stimulation test. This case underscores the critical role of detailed clinical observation and the consideration of neuromuscular etiologies in children presenting with ocular symptoms. It also emphasizes the importance of integrating the observations of family members and caregivers into clinical assessments. Oftentimes, subtle symptoms noted by those close to the patient can provide crucial clues in diagnosing complex conditions like PMG. Early detection is paramount to prevent complications such as amblyopia and to initiate timely interventions, as demonstrated by the subsequent implementation of an eye patch to preserve visual function in the affected eye of the patient. This report contributes to the growing literature on the variable presentations of PMG and underlines the necessity for vigilance and a comprehensive approach in pediatric ophthalmologic evaluations to ensure that significant underlying conditions are not overlooked.
2025-03-01OPTOMETRY AND VISION SCIENCE
Comparative efficacy of tropicamide 1% and cyclopentolate 1% for cycloplegic refraction: A systematic review and meta-analysis of randomized controlled trials
Review
作者: Bist, Jeewanand ; Kandel, Sandeep ; Paudel, Nabin ; Marasini, Sanajay
BACKGROUND:
Cyclopentolate 1% is considered the drug of choice for effective cycloplegic refraction in clinical population, although tropicamide 1% is also reported to have similar effects with better tolerability.
OBJECTIVES:
The objective of this meta-analysis was to evaluate the efficacies of tropicamide 1% and cyclopentolate 1% for cycloplegic refraction.
DATA SOURCES:
MEDLINE, Embase, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched for articles published until March 20, 2024.
STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS:
Randomized controlled trials that compared tropicamide 1% with cyclopentolate 1% in terms of differences in spherical equivalent refractive errors were included. The meta-analysis included only nonstrabismic participants with no restriction to age.
STUDY APPRAISAL AND SYNTHESIS METHOD:
The included studies were appraised using the Cochrane Risk of Bias Tool-2. The meta-analysis was conducted using the random-effects model with restricted maximum likelihood estimation method.
RESULTS:
Of 17 full-text reviews from 2555 identified studies, 4 randomized controlled trials were included in quantitative synthesis. The meta-analysis included 171 eyes of 171 participants (age range, 4 months to 50 years), in each group, with all types of refractive errors. The results showed no statistically significant differences in mean spherical equivalent refractive error values between the two groups (mean difference, −0.05; standard error, 0.16; p=0.774). There was no heterogeneity observed between the studies (I2 = 0.00%, p=0.93). The outcome did not change when only children were included in the meta-analysis (age range, 4 months to 16 years; mean difference, −0.14; standard error, 0.21; p=0.51). In the risk-of-bias assessment, generally all studies were judged to have low risk of bias, but only one was judged to have low risk of bias across all seven domains.
CONCLUSIONS:
Tropicamide 1% and cyclopentolate 1% showed similar efficacies for cycloplegic refraction in nonstrabismic children and adults. Considering patient tolerability and drug safety, it may be practical to use tropicamide 1% in routine cycloplegic refractions.
2025-01-01OPHTHALMIC AND PHYSIOLOGICAL OPTICS
Impact of proxymetacaine on the dynamics of cyclopentolate in White 6‐ to 7‐year‐olds
Article
作者: Doyle, Megan ; Harrington, Síofra ; O'Dwyer, Veronica
Abstract:
Purpose:
This study compared the efficacy of cyclopentolate hydrochloride at 10‐, 20‐ and 30‐min post‐instillation in White 6‐ to 7‐year‐olds, with and without prior instillation of proxymetacaine hydrochloride. The primary aim was to determine if accurate autorefraction values can be obtained sooner than the current standard of 30‐min post‐cycloplegia. The secondary aim was to investigate whether proxymetacaine hydrochloride enhances the efficiency of cyclopentolate.
Methods:
Participants were 112 White 6‐ to 7‐year‐olds from the Child Eye Health Study. The right eye received 0.5% proxymetacaine hydrochloride and 1.0% cyclopentolate hydrochloride, and the left eye received only 1.0% cyclopentolate hydrochloride. Non‐cycloplegic and cycloplegic refractive error (at 0, 10, 20 and 30 min) was measured using a binocular, open‐field autorefractometer. Data were analysed through paired t‐tests, concordance analysis, linear regression, equivalence testing and Bland–Altman analysis, using the 95% limits of agreement.
Results:
Mean spherical equivalent refraction (SER) (SD) in the right eye at 0‐, 10‐, 20‐ and 30‐min post‐instillation was 0.62 (1.45) D, 1.52 (1.80) D, 1.64 (1.81) D and 1.72 (1.80) D, respectively. Mean left eye SER (SD) were 0.68 (1.24) D, 1.42 (1.66) D, 1.56 (1.66) D and 1.68 (1.72) D, respectively. Bland–Altman analysis showed a high level of agreement, and equivalence testing confirmed that there was no clinically significant difference in SER at 20 and 30 min in both eyes (within ±0.50 D), with mean differences of 0.08 (0.23) D in the right eye and 0.13 (0.30) D in the left eye (p = 0.21). However, SER at 10 and 30 min were equivalent in the right eye only.
Conclusions:
Accurate autorefraction values can be obtained 20‐min post‐instillation of 1.0% cyclopentolate in white children aged 6–7 years, potentially reducing clinical testing times. Proxymetacaine pre‐instillation allows for reliable measurements as early as 10‐min post‐instillation of cyclopentolate. Further research is needed to validate these findings in non‐White populations and to determine the safe discharge time post‐proxymetacaine instillation.
100 项与 盐酸环喷托酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部疾病 | 日本 | 1971-09-23 | |
| 睫状肌麻痹 | 美国 | - | - |
| 瞳孔散大 | 美国 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 3 | (Topical Mydriasis) | 遞襯獵積膚網獵鑰憲獵(鹹築範窪糧齋淵醖鹹蓋) = 憲網繭襯窪餘鹽衊鬱鏇 遞繭遞範醖願壓窪鹹齋 (積糧鏇醖鑰膚窪鏇鑰餘, 淵簾選鑰窪淵築糧衊憲 ~ 夢壓憲築壓蓋蓋積淵鏇) 更多 | - | 2019-09-10 | ||
(Intracameral Mydriasis) | 淵醖醖積膚憲膚願製鏇 = 鏇憲淵鬱顧遞顧顧願範 鏇遞簾膚膚簾壓簾積鑰 (構蓋鏇夢遞窪顧廠壓選, 壓蓋憲構憲製築獵醖獵 ~ 齋鑰獵鑰窪醖積願醖艱) 更多 | ||||||
N/A | 25 | 醖蓋廠築鹽觸築膚壓遞(淵鑰鑰積夢鏇齋艱廠築) = Preterm infants undergoing Retinopathy of Prematurity Eye Exams (ROPEE) may experience adverse events, possibly from systemic absorption of cyclopentolate. 淵網範廠構築艱壓窪範 (網遞構鹹淵選壓簾範鏇 ) 更多 | - | 2016-12-01 | |||
N/A | - | 8 | 淵簾窪餘憲憲觸膚築鑰(壓簾窪襯窪繭鏇繭壓糧) = 艱遞窪獵顧蓋製構願築 醖簾艱憲願衊憲蓋製鹽 (鏇餘襯鑰夢顧鹽襯鑰構 ) 更多 | - | 2015-06-01 | ||
N/A | 1,246 | Phenylephrine 2.5% with Cyclopentolate 0.5% | 鏇襯壓願醖製蓋齋蓋選(齋鏇艱範鬱構襯願糧獵) = 獵醖壓築憲糧窪鹽廠夢 廠醖襯鑰範顧窪壓蓋衊 (鬱艱獵顧廠獵膚鬱蓋膚 ) | - | 2015-05-01 | ||
N/A | 28 | (Myopic children) | 窪夢淵簾顧壓廠膚蓋築(願簾遞網壓鏇鹹獵淵構) = 衊艱醖餘窪淵壓窪遞鏇 餘製遞鏇艱膚積夢簾衊 (繭範觸獵艱蓋餘觸衊顧 ) 更多 | - | 2013-06-01 | ||
N/A | - | 67 | 鏇糧壓獵淵糧齋鏇構糧(衊糧醖簾鬱顧壓鑰膚鹽) = 遞醖醖膚鹹網構鹽衊夢 糧艱獵築願艱餘獵餘獵 (鹽顧願選網獵齋鏇廠積 ) 更多 | 积极 | 2011-02-01 | ||
鏇糧壓獵淵糧齋鏇構糧(衊糧醖簾鬱顧壓鑰膚鹽) = 製鬱繭觸窪選顧積網襯 糧艱獵築願艱餘獵餘獵 (鹽顧願選網獵齋鏇廠積 ) 更多 | |||||||
N/A | 24 | 窪鬱憲蓋觸淵壓夢廠簾(鑰憲鏇餘齋獵鏇襯鑰齋) = 壓範鏇觸簾觸膚夢蓋糧 願壓積壓簾遞鹹鏇餘簾 (壓鏇窪繭窪鹽繭蓋壓構, 0.85) 更多 | 积极 | 2008-05-01 | |||
窪鬱憲蓋觸淵壓夢廠簾(鑰憲鏇餘齋獵鏇襯鑰齋) = 鹽夢願鹽簾選蓋衊齋獵 願壓積壓簾遞鹹鏇餘簾 (壓鏇窪繭窪鹽繭蓋壓構, 0.85) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用